Photoplethysmography (PPG) is a non-invasive technique to measure heart rate at a lower cost, and it has been recently widely used in smart wearable devices. However, as PPG is easily affected by noises under high-intensity movement, the measured heart rate in sports has low precision. To tackle the problem, this paper proposed a heart rate extraction algorithm based on self-adaptive heart rate separation model. The algorithm firstly preprocessed acceleration and PPG signals, from which cadence and heart rate history were extracted respectively. A self-adaptive model was made based on the connection between the extracted information and current heart rate, and to output possible domain of the heart rate accordingly. The algorithm proposed in this article removed the interference from strong noises by narrowing the domain of real heart rate. From experimental results on the PPG dataset used in 2015 IEEE Signal Processing Cup, the average absolute error on 12 training sets was 1.12 beat per minute (bpm) (Pearson correlation coefficient: 0.996; consistency error: -0.184 bpm). The average absolute error on 10 testing sets was 3.19 bpm (Pearson correlation coefficient: 0.990; consistency error: 1.327 bpm). From experimental results, the algorithm proposed in this paper can effectively extract heart rate information under noises and has the potential to be put in usage in smart wearable devices.
Algorithms ; Heart Rate/physiology* ; Photoplethysmography/methods* ; Signal Processing, Computer-Assisted ; Wearable Electronic Devices

Objective To evaluate the efficacy,safety and economy of cyclin-dependent kinase 4/6(CDK4/6)inhibitors for the first-line treatment of hormone receptors positive(HR+),human epidermal growth factor receptor 2 negative(HER2-)advanced breast cancer(ABC)by rapid health technology assessment,and to provide evidence for clinicians and policymakers.Methods PubMed,Cochrane Library,Embase,CNKI,WanFang Data,VIP databases and the official website of health technology assessment(HTA)agency were electronically searched to collect clinical evidence and literature of CDK4/6 inhibitors in the treatment of HR+/HER2-ABC from the inception to December 31,2023.Two reviewers independently identified studies,extracted data,assessed the quality of included studies,and descriptively analyzed and summarised the results.Results A total of 33 articles were included,including 9 systematic reviews/Meta-analyses,15 pharmacoeconomic studies and 9 HTA reports.In terms of efficacy,compared with endocrine therapy alone,the addition of CDK4/6 inhibitors significantly improved progression-free survival(PFS)and overall survival(OS)in patients with HR+/HER2-ABC(P＜0.05),but there was no significant difference in efficacy among palbociclib,abemaciclib and ribociclib(P＞0.05).In terms of safety,more adverse events were observed in patients treated with CDK4/6 inhibitors when compared with endocrine therapy(P＜0.05).There was a difference in the incidence of adverse effects between the different CDK4/6 inhibitors,with palbociclib having higher incidence of haematological adverse effects(P＜0.05),and abemaciclib being more likely to cause gastrointestinal adverse reactions such as diarrhoea(P＜0.05).The economic evaluation results were variable due to differences in healthcare costs,analysis perspectives,willingness-to-pay thresholds,and study duration in different countries.Conclusion CDK4/6 inhibitors have similar efficacy in the first-line treatment of HR+/HER2-ABC patients,but there are some differences in aspects such as safety and economy.